Drugs / initumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06868017 | Apr 2025 → Feb 2026 overdue | HER2 positive breast carcinoma | The First Hospital of Jilin University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | initumab | “Cohort A will receive initumab at initial load dose of 8mg/kg and maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses” NCT06868017 ↗ |
| Route | Intravenous | “maintenance dose of 6mg/kg intravenously” NCT06868017 ↗ |